Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 3, 2009, Pages 277-282

  Dalaker, M ^a   Bonesronning J H ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Azathioprine; Infliximab; Methotrexate; Psoriasis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTHROPATHY; ARTICLE; CHILD; CHLAMYDIASIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HERPES LABIALIS; HUMAN; LEG EDEMA; LUNG EMBOLISM; LYMPHADENOPATHY; MAINTENANCE THERAPY; MALE; MEDICAL RECORD REVIEW; PATIENT CODING; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSTATITIS; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SKIN ABSCESS; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60049085129     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.03039.x     Document Type: Article

References (18)

1. Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor-α in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 2003 12 : 190 194.
2. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002 46 : 1 23.
3. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001 357 : 1842 1847.
4. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 542.
5. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 1374.
6. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 56 : 31. e1 31. e15.
7. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003 48 : 829 835.
8. Kalb RE, Gurske J. Infliximab for treatment of psoriasis. Clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 2005 53 : 616 622.
9. Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis. a retrospective study of 73 patients. J Drugs Dermatol 2006 5 : 251 254.
10. Smith CH, Jackson K, Bashir SJ et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 2006 155 : 160 169.
11. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999 354 : 1932 1939.
12. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006 23 : 451 463.
13. Eklund KK, Peltomaa R, Leirisalo-Repo M. Occurrence of pulmonary thromboembolism during infliximab therapy. Clin Exp Rheumatol 2003 21 : 679.
14. Poulalhon N, Begon E, Lebbé C et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007 156 : 329 336.
15. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor á monoclonal antibody combined with low-dose weekly Methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 41 : 1552 1563.
16. Vermeire S, Noman M, van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007 56 : 1226 1231.
17. Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor á drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Result from a longitudinal, observational, multicenter study. Arthritis Rheum 2008 59 : 234 240.
18. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007 44 : 265 267.